Authors
Manel Puig-Domingo, Rosalind Way, Raquel Ciriza, Andrea Giutina
Published in
Pituitary. Volume 29. Issue 6. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
In the European Union (EU) and the United Kingdom (UK), the Summaries of Product Characteristics (SmPC) of pegvisomant (PEGV) and pasireotide LAR (PAS-LAR) require inadequate control on prior somatostatin analogue treatment (or intolerance for PEGV), unlike US labelling. These regulatory differences should be distinguished from inequalities in actual treatment access.
To assess whether these regulatory differences remain justified in light of predictive evidence, current consensus recommendations and patient needs.
Narrative review of EU and UK regulatory documents, pivotal trials, consensus statements and biomarker-guided trials, integrated with the patient perspective.
Validated clinical, imaging, functional and pathological predictors identify patients with a low probability of fgSRL response. Updated consensus guidelines increasingly recognize the importance to use biomarker-guided treatment rather than trial-error strategy choice and recommended as the best care modality allowing aalthough response predictors for first-generation somatostatin receptor ligands (fgSRLs) differ in accuracy and clinical readiness and for PAS-LAR they still remain to be confirmed .
Patients and clinicians propose reconsidering labels to enable earlier individualized treatment in selected patients, subject to drug-specific evidence and safety monitoring. This proposal extends beyond current recommendations for PAS-LAR; label harmonization would allow equitable access.
PMID:
43050034
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0